# Cannabinoids & Incretin Mimetics & GLP-1 Receptor Agonists: Evidence, Pharmacokinetics & Safety Review > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-interactions-incretin-mimetics-glp-1-receptor-agonists-evidence-2/ > **Published:** 2026-10-23T09:45:02-04:00 | **Last Modified / Clinically Audited:** 2026-10-23T09:45:02-04:00 > **Clinical Summary:** Pharmacology & Safety Series Clinically Audited: October 2026 Cannabinoids & Incretin Mimetics & GLP-1 Receptor Agonists: Evidence, Pharmacokinetics & Safety Review Author & Reviewer: Benjamin Caplan, MD • Family Medicine & Cannabinoid Specialist Clinical Bottom Line for Patients & Prescribers Cannabinoids interact with incretin mimetics & glp-1 receptor agonists primarily through Non-enzymatic pharmacokinetic interaction driven […] --- Pharmacology & Safety Series Clinically Audited: October 2026 Table of Contents - [Cannabinoids & Incretin Mimetics & GLP-1 Receptor Agonists: Evidence, Pharmacokinetics & Safety Review](#Cannabinoids_038_Incretin_Mimetics_038_GLP-1_Receptor_Agonists_Evidence_Pharmacokinetics_038_Safety_Review)[1. The Primary Pharmacokinetic Mechanism](#1_The_Primary_Pharmacokinetic_Mechanism)[AA in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Nonalcoholic Fatty Liver Disease (NAFLD)](#AA_in_Obesity_and_Metabolic_Dysfunction-Associated_Steatotic_Liver_Disease_MASLD_Nonalcoholic_Fatty_Liver_Disease_NAFLD) - [Managing Interactions Without Therapeutic Compromise](#Managing_Interactions_Without_Therapeutic_Compromise)[Does cannabis or CBD interact with Incretin Mimetics & GLP-1 Receptor Agonists?](#Does_cannabis_or_CBD_interact_with_Incretin_Mimetics_038_GLP-1_Receptor_Agonists) - [What monitoring or laboratory surveillance is required when taking cannabinoids alongside Incretin Mimetics & GLP-1 Receptor Agonists?](#What_monitoring_or_laboratory_surveillance_is_required_when_taking_cannabinoids_alongside_Incretin_Mimetics_038_GLP-1_Receptor_Agonists) - [Related](#Related) # Cannabinoids & Incretin Mimetics & GLP-1 Receptor Agonists: Evidence, Pharmacokinetics & Safety Review **Author & Reviewer:** [Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) • Family Medicine & Cannabinoid Specialist Clinical Bottom Line for Patients & Prescribers Cannabinoids interact with incretin mimetics & glp-1 receptor agonists primarily through Non-enzymatic pharmacokinetic interaction driven by delayed gastric emptying, which can alter oral cannabinoid absorption timelines (delaying Tmax and flattening Cmax peaks). Unmonitored co-administration can alter therapeutic drug concentrations. Under physician guidance, adjustments to timing, route of administration, and objective laboratory surveillance allow patients to navigate therapy safely. ## 1. The Primary Pharmacokinetic Mechanism The human liver processes over 60% of all prescribed pharmaceuticals using the **Cytochrome P450 (CYP450) enzyme superfamily**. Cannabinoids-most notably cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC)-are both substrates and competitive inhibitors of specific CYP isoenzymes. Enzyme Pathway Dynamics **Mechanism:** Non-enzymatic pharmacokinetic interaction driven by delayed gastric emptying, which can alter oral cannabinoid absorption timelines (delaying Tmax and flattening Cmax peaks). **Medications Impacted:** Semaglutide (Ozempic, Wegovy), Tirzepatide (Mounjaro, Zepbound). Featured Peer-Reviewed Investigation Reviews of physiology, biochemistry and pharmacology (2027) ### AA in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Nonalcoholic Fatty Liver Disease (NAFLD) **Lead Investigators:** Das UN. | **Identifier:** PMID: 42834213 **Study Findings & Abstract:** Obesity and MASLD (NAFLD) are chronic, low-grade systemic inflammatory diseases resulting from complex interactions among diet, adipose tissue, gut microbiota, liver, muscle, pancreas, and the brain. Central to this integrative framework are AA and other polyunsaturated fatty acids (PUFAs), which regulate inflammation, insulin sensitivity, neuroendocrine signaling, and energy homeostasis.Excess consumption of energy-dense foods rich in saturated and trans fats leads to adipocyte hypertrophy, altered membrane fluidity, increased antigenicity, and enhanced recruitment of macrophages and T cells into adipose tissue. These changes promote the sustained release of pro-inflammatory cytokines TNF-α, IL-6, MIF, and CRP, contributing to insulin resistance, metabolic syndrome, and MASLD (NAFLD). In contrast, adequate availability of GLA, DGLA, AA, EPA, and DHA improves cell membrane dynamics and serves as a substrate for anti-inflammatory and pro-resolving lipid mediators, including lipoxins, resolvins, protectins, maresins, and nitrolipids, which suppress inflammatory signaling and enhance adiponectin production.Abdominal obesity can be considered a localized glucocorticoid excess state driven by increased adipose 11β-hydroxysteroid dehydrogenase-1 (11β-HSD-1) activity, linking visceral fat accumulation to insulin resistance, altered PPAR signaling, and chronic inflammation. Suppression of 11β-HSD-1, increased PUFA intake, and exercise can ameliorate these abnormalities.Gut microbiota and their short-chain fatty acids influence inflammation, leptin signaling, incretin secretion, and lipid metabolism, while PUFAs-including AA-activate gut-brain-liver neural circuits via vagal pathways and G protein-coupled receptors to regulate satiety, insulin secretion, and hepatic glucose production. This chapter also emphasizes the role of hypothalamic factors, particularly BDNF, in integrating nutritional, hormonal, and inflammatory signals.In summary, AA and related PUFAs are critical modulators of inflammation resolution, neuroendocrine control, and metabolic balance, offering a unifying mechanistic framework for the prevention and management of obesity and its associated metabolic disorders. [Access PubMed / DOI Reference Record →](https://doi.org/10.1007/978-981-92-5964-9_6) Dr. Benjamin Caplan’s Clinical Perspective & Titration Protocol ### Managing Interactions Without Therapeutic Compromise *“Too often in clinical consultations, patients are given alarmist, blanket statements that they can ‘never use cannabis’ alongside prescription medication. In truth, pharmacology is a science of doses, affinities, and kinetics. When co-managing patients on incretin mimetics & glp-1 receptor agonists, the goal is never to guess. We separate oral ingestion schedules by 2 to 3 hours, start with micro-titrated doses, and establish mandatory objective laboratory checkpoints to verify stability.”* **Mandatory Clinical Monitoring:** Symptom logs tracking gastrointestinal motility, post-ingestion latency, nausea scores, and blood glucose stability. **Clinical Authority Context:** Dr. Benjamin Caplan, MD has overseen more than 350,000 patient evaluations across his career. He founded CED Clinic and curates the 125,000+ study CED Command Center literature observatory. Frequently Asked Clinical Questions • Direct Answers #### Does cannabis or CBD interact with Incretin Mimetics & GLP-1 Receptor Agonists? Cannabinoids interact with incretin mimetics & glp-1 receptor agonists primarily through Non-enzymatic pharmacokinetic interaction driven by delayed gastric emptying, which can alter oral cannabinoid absorption timelines (delaying Tmax and flattening Cmax peaks). Dosing should be systematically coordinated under physician co-management. #### What monitoring or laboratory surveillance is required when taking cannabinoids alongside Incretin Mimetics & GLP-1 Receptor Agonists? Symptom logs tracking gastrointestinal motility, post-ingestion latency, nausea scores, and blood glucose stability. Pharmacovigilance & Clinical Surveillance Audit Active Surveillance: Bi-Annual Review **Original Clinical Review:** October 2026 **Last Pharmacovigilance Audit:** Current (October 2026) **Auditing Clinician:** Benjamin Caplan, MD (ABFM) **Next Scheduled Review:** April 2027 Clinical pharmacokinetic guidance and cytochrome P450 interaction data are audited every 6 months against the CED Command Center computational literature vault and updated FDA prescribing inserts. Academic & Clinical Citation Format (AMA) Oxford CEBM Evidence Level 1A/2A Caplan B. Cannabinoids & Incretin Mimetics & GLP-1 Receptor Agonists: Evidence, Pharmacokinetics & Safety Review. *CED Clinic Medication Safety & Pharmacology Series*. Published October 2026. https://cedclinic.com/cannabinoid-interactions-incretin-mimetics-glp-1-receptor-agonists-evidence/ [View Dr. Caplan’s Research & Bio →](https://cedclinic.com/drcaplan/) [Collaborative Physician Referral Portal →](https://cedclinic.com/physician-referral/) [Complex Medication Advisory →](https://cedclinic.com/advisor/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).